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A B S T R A C T
The pattern of clinical behaviour and response to treatment of recurrent and/or metastatic head and neck
squamous cell carcinoma is heterogeneous. Treatment strategies that can be employed vary from potentially
curative salvage surgery and re-irradiation to palliative systemic therapies and best supportive care. The advent
of new therapeutic options, in terms of more sophisticated surgical approaches and techniques, highly conformal
and precise radiation techniques and immunotherapy may offer improved control of disease and longer survival.
Moreover, the epidemiological changes during the last decades, including the increase of human papilloma
virus-related oropharyngeal primary tumors, are also reflected in the recurrent and metastatic setting. In this
complex context the identification of predictive and prognostic factors is urgently needed to tailor treatment, to
increase its efficacy, and to avoid unnecessary toxicities. A better knowledge of prognosis may also help the
patients and caregivers in decision making on the optimal choice of care. The purpose of our review is to
highlight the current evidence and shortcomings in this field.
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1. Background
Recurrent and/or metastatic (R/M) head and neck squamous cell
carcinomas (HNSCCs) represent a group of highly heterogeneous pa-
tients and tumors. Their therapeutic strategy remains a challenge and
may vary widely from salvage surgery or re-irradiation with curative
intent, to systemic therapies with a palliative aim, up to the choice not
to perform any treatment for the progression of disease (Zafereo et al.,
2009; Chang et al., 2017; Janot et al., 2008; Heinonen et al., 2018).
Furthermore, the managing multidisciplinary team should consider
individual patient preferences, severity of symptoms and comorbidity
burden, life expectancy, quality of life, the toxicity of treatment and its
consequences in terms of surgical reconstruction or functional limita-
tions. Therefore, the availability of reliable prognostic and predictive
factors is of great importance both to guide the therapeutic approach
and to inform the patient and the caregivers.
It is important to clarify the difference between the definitions for
‘prognostic’ and ‘predictive’, as they are often used interchangeably. A
prognostic factor informs about outcome independent of the treatment
received, while a predictive marker relates to treatment results ac-
cording to biomarker positive or negative status (Ballman, 2015). Un-
like many other malignant diseases, R/M HNSCCs lack reliable pre-
dictive biomarkers.
2. Utility of prognosticators
Treatment of recurrent disease has a poorer survival outcome than
at the primary setting. However, favorable long-term survival outcomes
are reported in some cases of R/M HNSCCs treated with different
modalities (Leeman et al., 2017). Therefore, it is essential to obtain
tools for proper selection of patients to treatment programs with dif-
ferent intensity and to offer them the most appropriate treatment
modality in order to avoid unnecessary toxicities. For instance, in pa-
tients undergoing re-irradiation, comorbidities and pre-existing organ
dysfunction, defined as feeding tube or tracheostomy dependency, or
soft tissue defect, represent prognostic factors to differentiate between
short- and long-term survivors (Tanvetyanon et al., 2009). The median
overall survival (OS) rates of patients without any comorbidity or organ
dysfunction was 59.6 months compared with 5.5 months among those
with both of these 2 risk factors. Similarly, while the median survival
time of only 15.6 months has been reported for patients undergoing
salvage surgery, a subset of patients (20–40%) will have a long-term
survival benefit (Bachar et al., 2010; Hamoir et al., 2017; Tan et al.,
2010). Tan et al. found that patients with initial stage IV disease and
concurrent local and regional failures had markedly different survival;
having both, one or none of these parameters dramatically changed the
2-year survival rate (0%, 49% and 83%, respectively) (Tan et al., 2010).
In addition, in patients receiving palliative chemotherapy (CT), favor-
able predictors for 2-year survival have been described (Argiris et al.,
2004a). A small quote of long-term responders (5%) has been reported
also in patients receiving first-line palliative CT combined with an anti-
epidermal growth factor receptor (EGFR) agent (Vermorken et al.,
2014). Immunotherapeutic regimens can elicit durable responses in a
subset of patients, but these responses may be also delayed (Chow et al.,
2016). Thus, identification of patient-specific features that predict
treatment response and durable survival is important from both a
clinical and economic perspective.
Meanwhile, the landscape of HNSCCs has changed. On one hand, we
are witnessing the epidemiologic shift towards an increased rate of
human papilloma virus (HPV)-related oropharyngeal primaries. On the
other side, the spectrum of therapeutic armamentarium has widened
also in the R/M setting, with the advent of immunotherapy, the evo-
lution of surgical approaches and techniques, the use of modern ra-
diation treatment planning and delivery and the availability of proton-
and heavy ion-based radiotherapy (RT). Thus, our review is focused on
the evaluation of the existing literature concerning prognostic factors in
R/M HNSCC patients. For each therapeutic modality, we also con-
sidered, whenever possible, the predictive factors of response.
3. The role of HPV
The prognostic role of HPV in the curative setting remains highly
relevant also in the R/M setting. Several groups have reported an im-
proved outcome for relapsed HPV-positive disease treated with CT
(Spreafico et al., 2014), CT plus anti-EGFR agents (Vermorken et al.,
2013), or with multimodal approaches (Fakhry et al., 2014; Deeken
et al., 2015). More specific data will be reported in the following sec-
tions.
4. Potentially curative approaches
The strongest prognostic factor in R/M HNSCC is the feasibility of
surgical salvage and re-irradiation as the second choice. Interestingly,
factors that support the feasibility of these approaches are not clearly
defined yet, as the decision often relies on the clinical judgment of the
treating physician or the multidisciplinary tumor board, which renders
recommendations for treatment. However, some oncologic and clinical
issues are recognized as essential in determining if either surgery or re-
irradiation are feasible. Some prognostic factors are similar for both
types of treatment modalities, while others are specific only for one
treatment approach.
Performance status, age and comorbidity status are clinical char-
acteristics that may help physicians in defining the best therapeutic
strategy and balancing between expected toxicities and oncologic out-
come. As previously reported, comorbidities and organ dysfunction
caused by previous treatments and existing disease could well define
life expectancy in the R/M HNSCC setting (Tanvetyanon et al., 2009).
The Charlson comorbidity index, incorporating also age, showed to be a
significant predictor of death within 1 year of salvage treatment (Kim
et al., 2015).
Before any choice for salvage treatment with possible curative in-
tent, the presence of distant metastasis should be ruled out with an
accurate imaging.
5. Salvage surgery
To achieve a chance on cure by surgery (alone) in recurrent HNSCC,
all margins should be clear from tumor. The use of either regional or
free-flap reconstruction may offer the opportunity of wider resection
and thus achieving more frequently negative margins and therefore,
better outcomes. However, wide margins will remain difficult to obtain
close to important structures, e.g. carotid artery. Goodwin performed a
meta-analysis of 32 studies with a total of 1080 patients (laryngeal
41%, pharyngeal 32%, oral cavity cancer 24%) and reported a 5-year
survival rate of 39% (Goodwin, 2000). Similar survival figures have not
been reported in the radiotherapy series, which clearly points out the
importance of patient selection for salvage surgery and the existence of
a selection bias with prognostically less favorable patients being usually
directed to non-surgical treatment programs. Patients with unresectable
disease (i.e., with extension to prevertebral fascia or skull base or tumor
encasing the carotid artery) by definition are not candidates for a
curative salvage surgery. However, although it has no role in improving
survival, debulking surgery may be considered as a way to palliate
symptoms in highly selected cases, for instance in case of airway ob-
struction.
Several factors have been considered in determining prognosis of
R/M HNSCC patients referred for salvage surgery (Table 1).
Recurrent tumor in a previously irradiated or operated field gen-
erally has a poor prognosis. The subsite influences the outcome, with
laryngeal cancer showing relatively favorable survival outcomes com-
pared with other subsites (Hamoir et al., 2017; Goodwin, 2000;
Matoscevic et al., 2014; Ho et al., 2014). Salvage total laryngectomy,
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when accompanied by clear surgical margins, can result in 5-year OS
rates of 57–70% (Holsinger et al., 2006; Ganly et al., 2006; Sandulache
et al., 2016). In contrast, hypopharyngeal cancer has the poorest long-
term results after surgical salvage, due to the proximity of critical
structures such as the carotid artery or prevertebral fascia that makes it
difficult to attain clear surgical margins. Another contributing factor in
recurrent hypopharyngeal cancer is the high incidence of distant me-
tastasis. However, the impact of the treated site was found to be less
important than the stage of recurrence (Goodwin, 2000). Patients with
advanced recurrent primary tumors (rT3–4) and/or advanced recurrent
nodal disease (rN2–3) have a poorer outcome as compared with pa-
tients with early-stage recurrence (Zafereo et al., 2009; Goodwin, 2000;
Ho et al., 2014). This is likely due to the difficulty in obtaining clear
surgical margins in cases with higher T classification and by the higher
risk of complications due to more extensive surgery. In this regard, the
extent and complexity of resections represent indirect negative prog-
nostic factors. In addition, recurrent disease differs from primary tu-
mors as it typically has an infiltrative and multifocal growth, spreading
in microscopic deposits extending beyond the initial tumor boundaries,
which often preclude the achievement of free margins. Similarly, stage
at initial presentation remains prognostic, as higher initial stage of the
diseaseis associated with an increased risk of locoregional recurrence
and distant metastasis after salvage surgery (Tan et al., 2010; Taguchi
et al., 2016). A shorter disease-free interval predicts poorer outcome, as
evidenced by several reports (Zafereo et al., 2009; Kim et al., 2015; Liao
et al., 2008); generally, an interval of 6 months or less results in poorer
patient outcome.
Molecular justifications for these prognostic factors may be identi-
fied, applicable also to other treatment settings. As it is well known that
R/M HNSCCs have a different molecular profile than primary tumors
(Morris et al., 2016), it may be hypothesized that also primary cancers
with clinical dismal prognostic factors for survival at recurrence (higher
stage, lower disease-free interval) carry more deregulated genomic
features than those with better outcomes.
Positive margins or extracapsular spread has an increased risk for
recurrence in primary as well as salvage surgery setting; some reports
also show close margins as possible negative prognostic factors (Zafereo
et al., 2009; Hamoir et al., 2017; Tan et al., 2010; Ho et al., 2014;
Nichols et al., 2011). As most recurrences are in previously irradiated
areas, this increased risk cannot be always mitigated by adjuvant
treatment. Similarly, salvage surgery performed in patients who have
already received radiotherapy will result in a worse outcome than when
carried out in radiation-naïve subjects. This may be explained by both
the limitations in giving adjuvant radiotherapy and the likely increase
in radiation-induced cancer mutations resulting in more aggressive
behaviour.
Some authors have created a prediction modelling algorithm, which
utilizes the aforementioned factors. Hamoir et al. incorporated tumor
site, locoregional failure and initial stage in a prediction score that
stratified patients into four different disease-free specific survival (DFS)
outcomes, which varied between 29% and 96% at 2 years, according to
the presence of 3–0 bad prognostic factors (Hamoir et al., 2017). Tan
et al. also built a score considering initial stage IV tumors and con-
current local and regional failures: the presence of two factors gave a 2-
year OS rate of 0%, while in the absence of any of them the 2-year OS
was 83% (Tan et al., 2010). Unfortunately, the model suggested by (Tan
et al., 2010) could not be confirmed by Esteller et al. (Esteller et al.,
2011) and (Putten et al. (2015)). This may be caused by low numbers
and different cohorts of (selected) patients.
Gañán et al. using recursive partitioning analysis-derived have tried
to classify patients in function of the possibility of carrying out a sal-
vage surgery (Gañán et al., 2016). Considering initial T classification,
location of the tumor (laryngeal vs non-laryngeal), N classification,
time to recurrence and initial treatment they stratified patients into four
different groups with a possibility of carrying out potentially curative
salvage surgery, which varied between 15 and 81% depending on those
factors.
The outcome of patients treated with salvage surgery is also influ-
enced by HPV status: in the analysis of Guo et al., HPV-positive cancer
patients experienced a more favorable 2- and 3-year OS than their HPV-
negative counterparts (79 vs 57% and 67 vs 43%, respectively) (Guo
et al., 2015).
In recurrent oropharyngeal cancer, a systematic review and meta-
analysis of published trials showed a longer OS in patients treated with
potentially salvageable approaches in the post-2000 cohort (Jayaram
et al., 2016); this outcome benefit could be primarily due to the in-
crease in HPV-positive cancers over the last two decades and to the
improvement in surgical and radiotherapeutic techniques, as well as to
better patient’s selection. The same Authors also reported a longer 5-
year OS in patients receiving surgery as a salvage treatment in com-
parison to radiation therapy, even if this observation was verified only
in cohorts recruited before the year 2000 and again, it could be biased
by patient’s selection.
In case of recurrence of HPV-positive cancers, it has been proposed
that a multimodal intensive treatment, comprising also metasta-
sectomy, could benefit the patients, thus gaining prolonged OS (Deeken
et al., 2015). This HPV status should be tested on larger number of
patients, to confirm the positive prognostic effect of the multimodal
approach in HPV-positive cases.
The treatment approach to patients with oligometastatic disease is
often a challenge, as the role of surgical exeresis or radioablation of
distant disease is not clearly recognized and most patients are offered
systemic treatments. In the future, the identification of prognostic fac-
tors for oligometastatic patients and the use of more tailored inter-
ventions could prolong OS in these patients. One ongoing phase II trial
is comparing stereotactic radiotherapy combined with chemotherapy or
not for treatment of oligometastases in HNSCC (ClinicalTrials.gov
Identifier: NCT03070366).
6. Re-irradiation
Although salvage surgery is a preferred treatment option in re-
current disease after non-surgical treatment, only a minority of patients
are considered candidates for this strategy. However, re-irradiation has
attracted more attention as a potential therapy for recurrent HNSCCs
with the advent of modern RT techniques, such as intensity-modulated
radiotherapy (IMRT) and stereotactic RT. At this point it should be
underlined that there are no studies with head-to-head comparisonof
outcomes between surgical salvage and re-irradiation in recurrent
HNSCCs. Prognostic factors identified in the literature are reported in
Table 2. In such a scenario, the cumulative radiation dose and the vo-
lume of irradiated tissue must be thought fully considered to limit acute
and especially late toxicities. It is not only the dose delivered during
previous radiation that is important but also the time elapsed between
the two treatments and pre-existing toxicities, i.e. residual late sequelae
after the first RT. Because treatment options for alleviation of late se-
quelae of RT are limited and of variable benefit, the objective
Table 1
Comprehensive list of prognostic factors for salvage surgery identified in lit-
erature.
Salvage surgery
T and N stage at recurrence and at initial diagnosis
HPV status
Disease subsite (larynx vs other)
Disease-free interval
Surgical margins
Previous radiation therapy performed
Age
Performance status
Comorbidities
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assessment of existing sequelaeand a fair estimate of potential dete-
rioration by additional RT is of paramount importance (Strojan et al.,
2017). As recommended in a recent systemic literature review, re-ir-
radiation dose of ≥60 Gy and a volume encompassing the gross tumor
with up to a 5-mm margin should be pursued (Strojan et al., 2015). The
risk of severe late complications has been reported to be 20–40% and is
related to prior RT dose, recurrent tumor site, re-treatment RT dose,
treated volume and technique (Yamazaki et al., 2011). The disease
subsites with better outcome after re-irradiation are the larynx and
nasopharynx (Cacicedo et al., 2014; Takiar et al., 2016). As noted,
survival outcome needs to be balanced against the risk of significant
treatment-related toxicities that may impact on quality or quantity of
life. Choe et al., who analyzed 166 patients re-irradiated for recurrent
or second primary HNSCC, identified salvage surgery (before re-irra-
diation), previous chemo-RT, RT dose ≥60 Gyand the time interval
from previous RT of ≥36 months as significant independent prognostic
variables for prediction of OS (Choe et al., 2011). The MD Anderson
Cancer Center group evaluated the prognostic factors in 206 patients re-
irradiated with IMRT and, at multivariate analysis, they found that
performance status and response to induction CT are favorable prog-
nosticators of OS, while both nasopharyngeal initial site and response to
induction CT positively had positive impact on progression-free sur-
vival (PFS) (Takiar et al., 2016). Prognostic scores or nomograms to
select patients for re-irradiation have been described by several authors
(Leeman et al., 2017; Riaz et al., 2014; Ward et al., 2017). Tanvetyanon
et al. reported comorbidities, organ dysfunction, isolated neck recur-
rence, tumor volume and the interval between completion of previous
radiation and initiation of re-irradiation as parameters to predict the
probability of death within 24 months after re-irradiation (Tanvetyanon
et al., 2009). Using this nomogram, a good agreement between the
predicted and the observed outcomes was found with a concordance
index (0.75), showing a negligible chance of survival at 2 years after
reirradiation for most patients with organ dysfunction and comorbidity
and those who did not have an isolated nodal recurrence. More re-
cently, Ward et al. employed the recursive partitioning analysis to
discriminate cohorts of patients with distinct survival patterns after
reirradiation (Ward et al., 2017). They identified three different classes:
those> 2 years after the first treatment with resected tumors regardless
of definitive margin status;> 2 years after the first treatment with
unresected tumors or within 2 years without organ dysfunction; and
those within 2 years but with organ dysfunction; the corresponding 2-
year OS were 62%, 40% and 17%, respectively. Lastly, Riaz et al. built a
nomogram to predict locoregional control after re-irradiation: they
suggested to employ this tool for discrimination between the choice of
re-irradiation with curative or palliative intent (Riaz et al., 2014). The
factors involved were stage of recurrent disease, site of recurrence (oral
cavity carrying a worse prognosis), presence of organ dysfunction,
salvage surgery and RT dose. HPV status confirmed its positive prog-
nostic role also in patients re-irradiated for recurrence (Davis et al.,
2014; Velez et al., 2018).
Several authors reported that previous treatment with concurrent
chemo-RT was predictive for worse OS after re-irradiation (Choe et al.,
2011; Nagar et al., 2004), possibly due to more pronounced prolifera-
tion of fibrous tissue in the treated area after intensive chemoradiation
and/or the presence of a highly RT-resistant tumor clones in recurrent
tumor that survived initial chemo-RT. In poorly vascularized fibrotic
regions, drug delivery is compromized and RT-resistant hypoxic areas
are more extensive, which both reduce effectiveness of subsequent
treatment.
7. Systemic therapies
7.1. Chemotherapy
Table 3 resumes the main prognostic factors associated with sur-
vival in patients treated with CT for R/M HNSCCs. The prognostic role
of cancer-related hypercalcemia (CRH) in advanced solid tumors has
been analyzed in depth, particularly in R/M HNSCCs (Degardin et al.,
1995; Penel et al., 2008, 2009; Le Tinier et al., 2011; Liaw et al., 1990;
Ramos et al., 2017). Globally, CRH was linked to dismal OS ranging
from 35 to 91 days. Ramos et al. also demonstrated that systemic CT,
given after diagnosis of CRH, when feasible, leads to a meaningful
improvement in OS (144 days in CT-treated patients vs 25 days in no-
treated cohort; p= 0.001) (Ramos et al., 2017); however, existence of
selection bias in this report is rather possible. The gain of OS from re-
sponse to CT in R/M HNSCCs was described more than 25 years ago
(Ramos et al., 2017). Moreover, the two factors determining OS were
performance status and weight loss. These results were consistent with
what was observed by Argiris et al. in the largest retrospective analysis
of prognostic factors in R/M HNSCC patients treated with CT (Argiris
et al., 2004a). In multivariate analysis, additional three predictors of
poorer OS were identified: hypopharynx and oral cavity subsites, well-
to-moderate tumor differentiation and prior RT. After having added
response to CT into this prognostic model, all factors maintained their
statistical significance except for primary tumor subsite. Furthermore,
in overall response rate analysis, residual disease at the primary site
after first treatment with curative intent negatively impacted on out-
come.
When patients were divided between those with 0–2 negative
prognostic factors and those with 3–5, the OS was markedly different
(median OS: 0.98 vs 0.52 years, respectively). Among 399 patients in-
cluded in the Argiris’ analysis, only 13% were elderly (≥70 years old)
but age influenced only toxicities and not the survival outcomes (Argiris
et al., 2004b). Stell and McCormick identified two other important
predictors of OS, which were not previously described: site of recur-
rence (recurrence with distant metastasis had worse outcome than re-
lapse at the primary tumor site and the neck area) and time elapsed
from primary treatment to recurrence (Stell and McCormick, 1986).
From a biological point of view, the expression of EGFR ligands
showed a prognostic impact in patients treated with CT: a higher de-
tection rate (by immunohistochemistry) of amphiregulin was linked to
Table 2
Comprehensive list of prognostic factors with reirradiation identified in lit-
erature.
Reirradiation
T and N stage
HPV status
Disease subsite (larynx, nasopharynx vs other)
Disease-free interval
Previous RT dose received by critical structure
Treatment late toxicity
Tumor bulk or tumor volume
Salvage surgery feasible
Age
Performance status
Comorbidities
Table 3
Comprehensive list of prognostic factors with chemotherapy identified in lit-
erature.
Chemotherapy
Hypercalcemia
Weight loss
Performance status
Response to chemotherapy
Tumor differentiation
Primary tumor site
Previous radiotherapy
Site of recurrence
Time to first recurrence
HPV status
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worse prognosis with lower disease control rate and significantly
shorter PFS and OS (Tinhofer et al., 2011). These data, despite being
very intriguing, still need to be validated as they come from a retro-
spective analysis.
Spreafico et al. pooled the data of patients enrolled in three clinical
trials, analysing only CT-treated patients, to study the impact of HPV
status on the survival outcomes of R/M HNSCCs (Spreafico et al., 2014).
Even if the rate of HPV-positive patients was low (7–16% of the en-
rolled patients in these trials), they found that HPV conferred a favor-
able prognosis in CT-treated R/M HNSCCs (hazard ratio [HR] for
p16+=0.70; 95% CI: 0.52–0.93).
7.2. Anti-EGFR agents
In studies with anti-EGFR therapies for R/M HNSCCs, a prognostic
role of EGFR has never been identified, despite analysis of EGFR acti-
vation, expression, gene copy number and mutation (Bossi et al.,
2016a). To date, only rare EGFR polymorphisms confer a survival ad-
vantage, mainly dictated by the specific polymorphism EGFR R521 K. In
a phase II trial of R/M HNSCC patients treated with docetaxel plus
cetuximab, as second-line treatment, this EGFR polymorphism was able
to predict higher skin toxicity and an increased disease control rate with
longer PFS, however, without benefit in terms of OS (Klinghammer
et al., 2010). An OS advantage was reported in a second study in pa-
tients with advanced HNSCCs, carrying the same polymorphism and
treated with cetuximab ± CT (Stoehlmacher-Williams et al., 2012).
The whole transcriptome-based approach identified patients who
obtained a long-term response to EGFR inhibitors in combination with
CT (Bossi et al., 2016b). Tumor samples of patients experiencing long
PFS were enriched in expression of genes involved in EGFR signalling,
in intracellular catabolic processes, in tissue development including
upregulation of the epidermal differentiation complex genes; in con-
trast, the main gene-expression profile of short-term responders to
treatment was characterized by high expression of KRAS signalling
genes. This potentially predictive model of cetuximab sensitivity has
also been integrated and confirmed by miRNA analysis (De Cecco et al.,
2017).
In this scenario of prediction of response to anti-EGFR therapies, the
same group also detected specific transcript fusions in cetuximab-sen-
sitive patients (i.e. long noncoding RNA-containing fusions enriched
only in this subgroup) and in those refractory (i.e., CD274–PDCD1LG2
expressed in half of cetuximab-resistant patients without enrichment in
the cetuximab-sensitive group) (Bossi et al., 2017).
The prognostic role of HPV status is retained also in R/M HNSCC
patients when treated with anti-EGFR agents (Spreafico et al., 2014;
Bonner et al., 2017). However, when cetuximab is employed as single
agent and not synergizing with CT or radiation, the therapeutic benefit
seems to be confined to HPV-negative cases (Szturz et al., 2017).
7.3. Immunotherapy
In the last few years, several new investigational drugs have been
studied for HNSCC (Bossi and Alfieri, 2016), but the therapeutic ar-
mamentarium of this cancer has been mainly enriched by the im-
munotherapeutic agents (i.e. anti PD-1/PD-L1 agents). Unfortunately,
the benefit of immunotherapy is limited with approximately one out of
5 treated patients who respond to these novel compounds. Adding the
fact that at the current cost, these drugs are not cost effective (Tringale
et al., 2017), it is of paramount importance to identify the character-
istics of the patients and their disease responding to this treatment.
7.3.1. PD-L1/PD-L2 expression
In HNSCCs, regardless of any treatment performed, the significance
of PD-L1 expression is yet to be defined. A recent meta-analysis (Li
et al., 2017) of 17 cohort studies (total number of patients= 2869) did
not find any survival (OS and DFS) difference between PD-L1-positive
and -negative HNSCC patients. By subgroup analyses, the authors
identified a poorer survival outcome only for PD-L1 positive patients
from Asia (worse OS and DFS) and in those with tumors arising from
oral cavity (OS) or larynx, nasopharynx and salivary glands (DFS). On
the contrary, a negative prognostic role of PD-L1 overexpression on
circulating tumor cells has been identified at the end of treatment with
curative intent (induction chemotherapy followed by concomitant
chemoradiation) in locally advanced HNSCCs (Strati et al., 2017).
Given these observations, when patients with R/M HNSCC are
treated with immunotherapy, PD-L1 expression appeared to be a pre-
dictive factor for response. Notably, a higher PD-L1 expression is re-
lated to longer survival, both with nivolumab and pembrolizumab
treatment. In CheckMate-141 (Ferris et al., 2016), the phase III trial of
nivolumab in platinum-refractory R/M HNSCCs, where PD-L1 was de-
tected only on tumor cells, OS of patients whose tumors expressed PD-
L1 > 1% was 8.7 months (HR: 0.55; range: 0.36–0.83), while it was
5.7 months in those with PD-L1≤ 1% tumors (HR: 0.89; range:
0.54–1.45).The clinical benefit of PD-L1 positivity was also confirmed
in 2-year survival update of the CheckMate-141 (Ferris et al., 2018):
45% of risk of death less in tumors expressing PD-L1 > 1% (HR [95%
CI]= 0.55 [0.39-0.78]) in respect to 27% reported in PD-L1≤1% tu-
mors (HR [95% CI]= 0.73 [0.49–1.09]). However, it should be un-
derlined that CheckMate-141 trial was not statistically powered to
properly detect an OS difference between PD-L1 positive and PD-L1
negative patients. In the same nivolumab-treated population, Har-
rington at al (Harrington et al., 2017) also demonstrated a better pre-
servation of the patient-reported outcomes (PRO) when compared to
patients undergoing CT. The stabilization of symptoms and ability to
obtain a functioning status are of primary importance when evaluating
salvage therapy and may offer a prognostic tool to decide whether or
not to treat this fragile and heavily pre-treated patient population.
In Keynote-040 trial, the phase III trial of pembrolizumab in pla-
tinum-refractory R/M HNSCCs, patients carrying a disease with PD-L1
tumor proportion score (TPS) ≥50% had a median OS of 11.6 months
with pembrolizumab and 7.9 months with standard of care therapy
(HR: 0.54; range: 0.35–0.82) (Cohen et al., 2017). The method for de-
tection of PD-L1 also seems to play a role. In KEYNOTE-012, a phase Ib
study with pembrolizumab, PD-L1 was measured on tumor cells only as
well as on both tumor and immune cells (e.g. mononuclear in-
flammatory cells: stromal, T-lymphocytes, etc), the latter expressed as
Combined Proportion Score (CPS). Overall response rate (ORR) and
efficacy (OS+PFS) were higher in CPS PD-L1≥ 1% compared with
measuring PD-L1 on tumor cells only (TPS≥ 1%) (Chow et al., 2016).
Therefore, the immune cells involved in antitumor vigilance should be
considered since they possibly impact on response to anti-PD-1/anti PD-
L1 agents and their respective survival outcomes. In fact, in Keynote-
048 (Burtness et al., 2018), a phase III trial with 3 arms of mono-im-
munotherapy (pembrolizumab), immunotherapy combined with chemo
(pembrolizumab plus carboplatin or cisplatin + 5-fluorouracil) and
standard of care for first-line of R/M HNSCC (extreme regimen), both
CPS≥20% and CPS≥1% resulted predictors of higher OS in patients
treated with pembrolizumab when compared to the standard Extreme
schedule: (for CPS≥ 20%, HR [95% CI]= 0.61 [0.45-0.83] while for
CPS≥1%, HR [95% CI]= 0.78 [0.64-0.96]).
Two additional, anti-PD-L1 agents have been described that de-
monstrate safety and efficacy in R/M HNSCCs: atezolizumab (Balheda
et al., 2017) and durvalumab [732]. In a phase Ia study with atezoli-
zumab (Balheda et al., 2017), PD-L1 > 5% patients (n=25) had
better ORR (24%) and duration of response (DOR; 26.2 months) than
PD-L1 < 5% patients (n= 7; ORR: 14% and DOR: 7.4 months). A
phase II study with durvalumab (Zandberg et al., 2017) has been de-
signed selecting only patients whose tumors are highly PD-L1 positive
(> 25%, measured on tumor cells only) and reported 13.5% of ORR (15
out of 111 evaluable patients).
Another emerging prognostic factor, which is currently under in-
vestigation, is PD-L2. This target was detected on the cell surface of
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seven tumor types (Yearley et al., 2017): gastric, melanoma, kidney,
bladder, lung, breast (triple-negative) and HNSCCs. The latter was the
most PD-L2 enriched tumor type. PD-L2 expression could be a strong
predictive factor regardless of PD-L1, thus partially explaining re-
sponses in PD-L1-negative patients. In fact, patients with PD-L2-positive
tumors cells had longer PFS and improved OS compared with patients
with PD-L2-negative cells. Further prospective studies are awaited in
this setting.
7.3.2. Hpv
With regards to the impact of HPV status, the nivolumab study
(Strati et al., 2017) stated that patients with HPV+ tumors resulted
more likely to benefit from immunotherapy (HR for death [0.56] in
HPV+ compared with HR [0.73] in HPV-) but this was not confirmed
in the 2-years long-term survival update (Ferris et al., 2018).
Other studies have reported data in this regard. Specifically, in other
immunotherapy clinical trials with recurrent HNSCC patients (Chow
et al., 2016; Bauml et al., 2017), a trend towards a higher ORR in the
HPV+ subgroup was observed while it was not confirmed in the ate-
zolizumab (Balheda et al., 2017) and KEYNOTE-040 studies (Cohen
et al., 2017). For the time being, HPV status should not be used in
selecting R/M HNSCC patients to be treated with immunotherapy.
7.3.3. Microbiome
In the nivolumab trial (Ferris et al., 2016), no difference was shown
in the composition of saliva microbiome between responders and non-
responders patients.
Having said that, we need to highlight how salivary microbiome
profiling of the CheckMate-141 trial was just exploratory.
Considering also that the sample size was small, no final conclusions
can be drawn. Therefore, further evidence is urgently needed, as there
are no data available with regards to gut microbiome.
7.3.4. Immuno-signature
Other immuno-signatures may also predict treatment response. For
example, HNSCC tumors that express the IFN-gamma 6-gene expression
signature (IDO1, CXCL9, CXCL10, HLA-DRA, STAT1 and IFNG) showed
a higher response rate to immunotherapy and a longer PFS and OS
when compared to those without this gene signature (Seiwert et al.,
2015). Ayers et al. recently identified an IFN-gamma 18-gene signature
predicting outcomes in HNSCC patients treated by drugs acting on the
PD-1/PD-L1 axis (Ayers et al., 2017). IFN-gamma is reported to increase
PD-L1 expression, thus leading to the possibility to better exploit drugs
with activity on the PD-1/PD-L1 axis.
7.3.5. Tumor mutational burden
Tumor mutational burden (TMB) is another upcoming biomarker
potentially predicting outcomes in immune-oncology which deserves
consideration in this context. In general, we have learned that higher
TMB is correlated to higher probability of response to PD-1/PD-L1 axis
inhibition (Yarchoan et al., 2017). This is explained by the fact that
highly mutated tumors may have higher neoepitopes exposure thus
possibly increasing the immune response amplified through PD-1/PD-
L1 inhibition. This relationship between TMB and response to PD-1/PD-
L1 inhibition was also confirmed in virus negative cohort [HPV and
Epstein–Barr Virus (EBV)] of HNSCC (Hanna et al., 2018; Haddad et al.,
2017). Specifically, in the virus-related group of HNSCC, viral neoepi-
topes seem to be dominant versus somatic neoepitopes in the process of
immune system evasion (Haddad et al., 2017). Furthermore, Hanna
et al (Hanna et al., 2018) identified specific somatic frameshift events
(insertion and/or deletion of a nucleotide in a translating coding triplet)
in tumor suppressor genes able to significantly predict response to PD-
1/PD-L1 blockade. Haddad et al (Haddad et al., 2017) did not found a
correlation between TMB and tumor inflammation biomarkers [IFN-
gamma gene-expression profile (GEP)] in predicting immune response
in the HNSCC group. This is different from other cancer types (Long
et al., 2018), possibly due to the highest median intratumor infiltration
of immunosuppressive Treg/CD8+T cells, as reported for HNSCC
(Mandal et al., 2016).
8. Conclusions
In HNSCCs, the latest epidemiological changes and the introduction
of new therapeutic modalities are leading to different prognostic and
therapeutic scenarios for R/M disease. The ability to better define the
prognosis and likelihood of response for an individual patient should
allow more tailored therapeutic approaches, therebyavoiding treatment
modalities unlikely to be successful. This would consequently spare
patients from unnecessary risks of toxicities and the national healthcare
systems from avoidable costs. Furthermore, the identification of more
specific prognostic or predictive markers is also important from the
clinical research perspective. In this area, these factors could be used as
stratification variables within the clinical trials to optimize the study
design and better understand the results. Moreover, the combination of
multiple factors may also deserve investigation as a novel strategy to
potentiate the ability in predicting patients’ response or prognosis.
However, the routine use of predictive and prognostic biomarkers in
clinical decision making demands high levels of evidence to ensure
their validity. In that case, reliable prognostic or predictive information
might also be very helpful in discussions with patients and their fa-
milies when deciding on the best possible treatment scenario in the
setting of R/M HNSCC.
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